Dr. Michael Lazar

Immunotherapy may add years for prostate cancer patients

Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown. Researchers found that a small proportion of men were 'super responders' and were alive and well even after the trial had ended despite having had a very poor prognosis before treatment. The study found that one in 20 men with end-stage prostate cancer responded to the immunotherapy pembrolizumab -- but although the number who benefited was small, these patients sometimes gained years of extra life. The most dramatic responses came in patients whose tumors had mutations in genes involved in repairing DNA, and the researchers are investigating whether this group might especially benefit from immunotherapy. [...]

2019-12-10T09:21:43-08:00December 10th, 2019|

A Typical HIFU Procedure Day

Wake up, get ready, and head to the treatment facility. Patients will need to complete their bowel prep per their MD’s instruction. This is comparable to a prostate biopsy bowel prep. 6 am – 7 am | Arrive at treatment facility, be greeted by staff, and enter procedure preparation area. Patients will typically be asked to arrive at the treatment facility at least an hour before the procedure. 7 am – 10 am | Sonablate HIFU Procedure A typical HIFU procedure lasts between 2-4 hours (depending on the size of the prostate) and is either done under general anesthesia or an epidural and IV sedation. During the procedure a catheter will be put in place to help with urination, and will stay in [...]

2019-11-19T09:50:33-08:00November 12th, 2019|

Researchers aim for a paradigm shift in prostate cancer diagnosis

In combination with the current prostate specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment. Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has a low specificity (high false positives) with about 75 per cent of all PSA positive results ending up with negative biopsies that do not find cancer. When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and [...]

2019-11-26T10:05:32-08:00September 24th, 2019|

Prostate cancer risks may be lowered by mushroom consumption

A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer. A total of 36,499 men, aged 40 to 79 years who participated in the Miyagi Cohort Study in 1990 and in the Ohsaki Cohort Study in 1994 were followed for a median of 13.2 years. During follow-up, 3.3% of participants developed prostate cancer. Compared with mushroom consumption of less than once per week, consumption once or twice a week was associated with an 8% lower risk of prostate cancer and consumption three or more times per week was associated with a 17% lower [...]

2019-09-17T10:01:10-07:00September 17th, 2019|

Dr. Lazar Selected as Among Sonoma County’s Top Doctors

Santa Rosa urologist and prostate cancer expert Dr. Michael Lazar recognized in the field of Urology as one of the best physicians in Sonoma County. Every year, Sonoma Magazine’s Top Doctor survey polls Sonoma County doctors and medical specialists for physicians they most often recommend to a loved one. This year almost 500 professionals are noted in the September issue as “the crème de la crème” in more than 50 categories. Dr. Lazar was recognized by his medical peers in the field of urology. About Dr. Lazar “I am honored to be among the top doctors recommended by their peers again in this year’s survey,” says Dr. Lazar. “There are so many excellent physicians in Northern California and Sonoma County Magazine helps the highlight [...]

2019-09-10T10:12:37-07:00September 10th, 2019|

Dr. Lazar talks about HIFU for Prostate Cancer Awareness Month

Prostate cancer affects more then 3 million men every year, worldwide. Last year 1 in 9 men in the US were diagnosed with prostate cancer. Genes for disease can run in families. Men who have a relative with prostate cancer are twice as likely to develop the disease, while those with two or more relatives are nearly four times as likely to be diagnosed with prostate cancer themeselves. The risk is even higher when the affected family members were diagnosed before age 65. September is national Prostate Cancer Awareness Month. About 174,650 new cases of this type of cancer are reported each year, along with 31,620 deaths attributed to the disease annually. One in nine men will be diagnosed with prostate cancer during [...]

2019-09-10T09:54:18-07:00September 3rd, 2019|

Can an apple a day keep cancer away?

Consuming flavonoid-rich items such as apples and tea protects against cancer and heart disease, particularly for smokers and heavy drinkers, according to new research from Edith Cowan University (ECU). Researchers from ECU's School of Medical and Health Sciences analysed data from the Danish Diet, Cancer and Health cohort that assessed the diets of 53,048 Danes over 23 years. They found that people who habitually consumed moderate to high amounts of foods rich in flavonoids, compounds found in plant-based foods and drinks, were less likely to die from cancer or heart disease. Lead researcher Dr Nicola Bondonno said while the study found a lower risk of death in those who ate flavonoid-rich foods, the protective effect appeared to be strongest for those at high [...]

2019-08-20T08:52:58-07:00August 20th, 2019|

The Mighty Cancer Fighting Properties of Feverfew

Researchers at the University of Birmingham have shown that it's possible to produce a compound with anti-cancer properties directly from feverfew -- a common flowering garden plant. The team was able to extract the compound from the flowers and modify it so it could be used to kill chronic lymphocytic cells in the laboratory. Feverfew is grown in many gardens, and also commonly sold in health food shops as a remedy for migraine and other aches and pains. The compound the researchers were investigating is called parthenolide and was identified by scientists as having anti-cancer properties several years ago. Although available commercially, it is extremely expensive with poor "drug-like" properties and has not progressed beyond basic research. Researchers were able to show a [...]

2019-08-10T16:24:08-07:00August 10th, 2019|

Optimizing prostate cancer treatment options with HIFU

Creating a customized plan optimized for a patient’s specific prostate needs is easier with Sonablate HIFU prostate ablation. “Did you know that prostate cancer can be treated without suffering the side effects of surgery and radiation? I am Dr. Michael Lazar, 4 time board certified urologist, who’s practiced in Santa Rosa for 36 years.  In 2007, I investigated and became an early user of a new technology for treatment of prostate cancer called high intensity focused ultrasound, or HIFU. This exciting non-invasive technology uses ultrasound energy to create heat.  This heat is precisely aimed at the cancerous portions of the gland to kill the cancer while sparing the normal regions.  It is painless, bloodless and causes much less erectile dysfunction and almost no [...]

2019-07-23T09:57:44-07:00July 23rd, 2019|

Protein identified that promotes aggressive prostate cancer

Study seeks to uncover new strategies to prevent or treat aggressive, late-stage prostate cancerProstate cancer represents a major health challenge and there is currently no effective treatment once it has advanced to the aggressive, metastatic stage. A new has revealed a key cellular mechanism that contributes to aggressive prostate cancer, and supporting a new clinical trial. The study was published in the journal Clinical Cancer Research.The research led by investigators at the Sidney Kimmel Cancer Center -- Jefferson Health (SKCC) and their collaborators at Memorial Sloan Kettering Cancer Center, the University of California, San Francisco, and Celgene Corporation, focused on an enzyme called DNA-PK (DNA-dependent protein kinase), a pivotal component of the cellular machinery that controls both DNA repair and influences gene expression. The [...]

2019-07-03T10:33:46-07:00July 3rd, 2019|